Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 98.00 | |
25 mg | In stock | $ 197.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 493.00 | |
500 mg | In stock | $ 1,070.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma. |
Targets&IC50 | FAAH (human):7.24 μM, ABHD6 (human):1.79 μM, MAGL (human):46 nM, H1 receptor:6.81 (pA2) |
In vitro | JZP-361 shows the affinity of H1 antagonistic with a pA2 of 6.81). JZP-361(≤10 μM) does not show cannabinoid receptor activity. JZP-361 displays favorable interactions within the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole[1]. |
Synonyms | JZP361, JZP 361 |
Molecular Weight | 405.88 |
Formula | C22H20ClN5O |
CAS No. | 1680193-80-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 36.5 mg/mL (90.0 mM)
DMSO: 7.3 mg/mL (18.0 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JZP-361 1680193-80-9 Metabolism Lipase JZP361 JZP 361 inhibitor inhibit